Soleno Therapeutics (SLNO) Stock Analysis

What Soleno Therapeutics does

Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III clinical evaluation. Established in 1999, the Redwood City, California-headquartered firm adopted its current name, Soleno Therapeutics, Inc., in May 2017, having previously operated as Capnia, Inc.

Key metrics

ETFs linked to SLNO

Broad-market and Healthcare sector ETFs an investor holding Soleno Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how SLNO fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Soleno Therapeutics?

Soleno Therapeutics trades under the ticker SLNO on NASDAQ.

Which exchange is SLNO listed on?

SLNO is listed on NASDAQ.

What sector does Soleno Therapeutics operate in?

Soleno Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze SLNO in a portfolio?

PortView shows SLNO's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.